1. Home

Program

Filter activities

*Preliminary Program - subject to change.

Aluizio Marques Ballroom

13:30 - 14:00
Opening Ceremony

Opening Ceremony

14:00 - 16:00
Sessão

EM e NMO no Brasil: onde estamos em termo de acesso

14:00 - 14:20
A visão do Judiciário
14:20 - 14:30
Discussão
14:30 - 14:50
A visão da Indústria Farmacêutica
14:50 - 15:00
Discussão
15:00 - 15:20
A visão da CONITEC
15:20 - 15:30
Discussão
15:30 - 15:50
A visão da Saúde Suplementar
15:50 - 16:00
Discussão
16:00 - 16:30
Break

Break

16:30 - 18:00
Session

LACTRIMS and RIMS session: Enhacing rehabilitation in LATAM

16:30 - 16:50
Multidisciplinary care in MS: impact in the quality of life
16:50 - 17:00
Discussion
17:00 - 17:20
Physical Exercise in MS Rehabilitation: Progress, Key Learnings, and Ongoing Challenges
17:20 - 17:30
Discussion
17:30 - 17:50
PROMS and Multiact initiatives: perspectives and potential
17:50 - 18:00
Discussion
18:00 - 19:00
Symposium

Pharma Symposium I

19:00 - 20:00
Session

Neuroimunobol

19:00 - 20:00
Time Charcot
19:00 - 20:00
Time Devic

*Preliminary Program - subject to change.

Aluizio Marques Ballroom

07:40 - 08:00
Session

Platform presentations: 1 MS and 1 NMOSD

08:00 - 08:30
Symposium

PHARMA

08:30 - 11:00
Session

CTRIMS Session: MS and NMO in the world

08:30 - 08:50
ACTRIMS "Impact of the new MS criteria in North America"
08:50 - 09:00
Discussion
09:00 - 09:20
BCTRIMS "MS and NMOSD Databases in Brazil"
09:20 - 09:30
Discussion
09:30 - 09:50
PACTRIMS "NMOSD in India: Epidemiology and Clinical Features"
09:50 - 10:00
Discussion
10:00 - 10:20
LACTRIMS "NMO and Infections in Latin America"
10:20 - 10:30
Discussion
10:30 - 10:50
ECTRIMS "Current Status of MS Treatment in Europe"
10:50 - 11:00
Discussion
11:00 - 11:30
Break

Break

11:30 - 12:10
Lecture

Aluizio Marques Lecture

11:30 - 12:10
Rationale and Perspectives on the Future of NMO
12:10 - 13:10
Symposium

Pharma Symposium II

13:10 - 14:10
Session

Top 10 of the Year - Part I: Multiple Sclerosis - How these Papers Impact our Practice

14:10 - 15:50
Session

MS Session I

14:10 - 14:30
Chronic Active Lesions - from diagnosis to prognosis
14:30 - 14:40
Discussion
14:40 - 15:00
The road to remyelination
15:00 - 15:10
Discussion
15:10 - 15:30
Is it RRMS with PIRA or SPMS?
15:30 - 15:40
Discussion
15:40 - 15:47
Platform presentation 03
15:47 - 15:50
Discussion
15:50 - 16:20
Break

Break

16:20 - 17:30
Session

MS Session II

16:20 - 16:40
Regional considerations in the differential diagnosis of MS
16:40 - 16:50
Discussion
16:50 - 17:10
Updated evidence in DMTs discontinuation and de-escalation in MS
17:10 - 17:20
Discussion
17:20 - 17:27
Platform presentation 04
17:27 - 17:30
Discussion
17:40 - 18:40
Happy Poster

Happy Poster

*Preliminary Program - subject to change.

Aluizio Marques Ballroom

07:40 - 08:00
Session

Platform presentations: (5a MS a 6a NMOSD)

08:00 - 08:30
Symposium

PHARMA

08:30 - 10:10
Session

NMOSD Session I

08:30 - 08:50
Gaps in NMOSD research
08:50 - 09:00
Discussion
09:00 - 09:20
The Global Impact of Race on NMOSD: Epidemiology and Disparities
09:20 - 09:30
Discussion
09:30 - 09:50
NMOSD and its Outcome in Thai and Other Asian Populations
09:50 - 10:00
Discussion
10:00 - 10:07
Platform presentation 7 (NMOSD 7)
10:07 - 10:10
Discussion
10:10 - 10:40
Break

Break

10:40 - 11:50
Session

NMO Session II

10:40 - 11:00
The Growing Impact of Treatment on NMOSD Outcomes
11:00 - 11:10
Discussion
11:10 - 11:30
Cell therapy and tolerization in NMOSD
11:30 - 11:40
Discussion
11:40 - 11:47
Platform presentation 8
11:47 - 11:50
Discussion
11:50 - 12:50
Symposium

Pharma Symposium III

12:50 - 13:50
Session

Top 10 of the Year - Part II: NMOSD - How these Papers Impact our Practice

13:50 - 15:50
Symposium

ECF Symposium - The MS continuum: From Prodrome to Progression

13:50 - 14:10
Identifying the preclinical disease: the impact of the new 2024 MS criteria and going beyond
14:10 - 14:20
Discussion
14:20 - 14:50
Moving forward in halting MS progression: better outcomes measures or trial design?
14:50 - 14:50
Discussion
14:50 - 15:10
Novel concepts on disease progression: brain genetic resilience and immunological phenotypes
15:10 - 15:20
Discussion
15:20 - 15:40
Neuroimaging measures for progression: Glymphatic system/meningeal inflammation
15:40 - 15:50
Discussion
15:50 - 16:20
Break

Break

16:20 - 18:00
Session

Advances in Neuroimmunology: Diagnosis, Treatment, and Patient-Centered Care

16:20 - 16:40
Autoimmune encephalitis: treatment insights from the Brazilian Cohort (BRAIN)
16:40 - 16:50
Discussion
16:50 - 17:10
Combined Central and Peripheral Demyelination: New Insights in Diagnosis, and Treatment
17:10 - 17:20
Discussion
17:20 - 17:40
NMOSD Care from the Patient’s Perspective: What Every Doctor Should Know
17:40 - 17:50
Discussion
18:00 - 19:00
Happy Poster

Happy Poster

*Preliminary Program - subject to change.

Aluizio Marques Ballroom

07:30 - 08:00
Meeting the Expert

Meeting the Expert

08:00 - 10:00
Symposium

BCTRIMS NeuroImaging Symposium

08:00 - 08:20
Normal tissue appearing damage in NMO: what advanced MRI can add?
08:20 - 08:30
Discussion
08:30 - 08:50
Central vein sign and paramagnetic rim lesion evaluation in clinical practice: Application and pitfalls
08:50 - 09:00
Discussion
09:00 - 09:20
IA application in demylinating disorders
09:20 - 09:30
Discussion
09:30 - 09:50
Detection of infratentorial and spinal cord lesions: challenges and implications in MS
09:50 - 10:00
Discussion
10:00 - 10:30
Break

Break

10:30 - 12:00
Session

Pediatric Neuroimmunology

10:30 - 10:50
MRI predictors of the differential diagnosis of pediatric MS and MOGAD - how to apply the evidence from research in clinical practice
10:50 - 11:00
Discussion
11:00 - 11:20
Experience with the use of high-efficacy DMTs in pediatric patients with MS. Are they really superior to 1st line DMTs?
11:20 - 11:30
Discussion
11:30 - 11:50
Real life challenges in the diagnosis and treatment of pediatric NMOSD
11:50 - 12:00
Discussion
12:00 - 12:20
Closing Session

Closing Session